FAIR VALUE MEASUREMENTS

3 Months Ended

Oct. 31, 2025

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 5: FAIR VALUE MEASUREMENTS

The following table presents information about our financial instruments that are measured at fair value on a recurring basis as of October 31, 2025 and July 31, 2025:

		Fair Value Measurements at
		October 31, 2025												July 31, 2025
		Level 1				Level 2				Total				Level 1				Level 2				Total
Financial Assets:
Cash and cash equivalents			2,714,012				-				2,714,012				10,493,808				-				10,493,808
Short-term investments			7,461,960				-				7,461,960				7,372,473				-				7,372,473
Total assets measured at fair value		$	10,175,972			$	-			$	10,175,972			$	17,866,281			$	-			$	17,866,281

Financial liabilities:
Warrants liability			233,029				173,844				406,873				151,586				186,086				337,672

Total liabilities measured at fair value		$	233,029			$	173,844			$	406,873			$	151,586			$	186,086			$	337,672

BriaCell Therapeutics Corp

Notes to the Condensed Consolidated Financial Statements

(Unaudited, expressed in US Dollars, except share and per share data and unless otherwise indicated)

We classify our cash and cash equivalents and the liability in respect of publicly traded warrants within Level 1 because we use quoted market prices in active markets. The Company also holds Level 1 short-term investments with coupon rates ranging between 3% and 5.51%, which are measured using quoted prices in active markets.

The fair value of the warrant liability for non-public warrants is measured using inputs other than quoted prices included in Level 1 that are observable for the liability either directly or indirectly, and thus are classified as Level 2 financial instruments.